Trials / Completed
CompletedNCT00992147
Safety and Efficacy of Autologous Cultured Adipocytes in Patient With Depressed Scar
A Phase II/III Clinical Study of ANTG-adip for the Treatment of Depressed Scar to Evaluate Safety and Efficacy
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Anterogen Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Autologous cultured adipocytes (ANTG-adip) is produced by well-established techniques including cell harvesting from lipoaspirates, expansion of adipose tissue derived stem cells, and differentiation into pure and immature adipocytes. This was an open-label, dose-escalation study. Patients are given subcutaneous injection of ANTG-adip and followed for 12 weeks according to the clinical trial protocol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adipocell | autologous cultured adipocytes (ANTG-adip) |
Timeline
- Start date
- 2004-05-01
- Completion
- 2007-03-01
- First posted
- 2009-10-09
- Last updated
- 2009-10-09
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00992147. Inclusion in this directory is not an endorsement.